Hematology Xagena
Survival data from two Brentuximab vedotin ( Adcetris ) pivotal Phase 2 clinical trials in relapsed / refractory Hodgkin lymphoma ( R/R HL ) and relapsed / refractory systemic anaplastic large cell ly ...
Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, has achieved an overall response rate of 66%, as assessed by International Harmonization Project response criteria ( n=19/29: 95% CI, 46-82 ), in tran ...
The findings from KEYNOTE-087, the phase 2 study investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodgkin l ...
PD-1 blockade via Pembrolizumab ( Keytruda ) monotherapy has shown antitumor activity in relapsed or refractory classic Hodgkin lymphoma ( R/R cHL ). KEYNOTE-204 was a randomized, international, o ...
Mediastinal gray zone lymphoma ( MGZL ) is a rare form of non-Hodgkin lymphoma ( NHL ) with intermediate features between classical Hodgkin lymphoma ( cHL ) and primary mediastinal B-cell lymphoma ( P ...
A phase 1-2 study evaluated Brentuximab vedotin ( Adcetris ) combined with Nivolumab ( Opdivo ) as first salvage therapy in patients with relapsed/refractory ( r/r ) classical Hodgkin lymphoma ( cHL ...
Results from the ongoing pivotal phase 2 clinical trial of Camidanlumab tesirine ( Cami ) in relapsed or refractory ( r/r ) Hodgkin lymphoma were presented at the European Hematology Association 2022 ...
Camidanlumab tesirine, an antibody-drug conjugate comprising a human IgG1 anti-CD25 monoclonal antibody conjugated to a pyrrolobenzodiazepine ( PBD ) dimer, displayed antitumor activity and manageable ...
